Promising Results from First-in-Human Clinical Trial of New Drug

Understanding Vascular Calcification in Hemodialysis Patients

A recent clinical trial has provided encouraging findings regarding a new drug aimed at reducing vascular calcification in patients undergoing hemodialysis. Vascular calcification is a significant concern as it remains the leading cause of mortality among individuals with end-stage renal disease who are on hemodialysis. As highlighted by The US Renal Data System, nearly half of these patients succumb to vascular disease, largely due to rapid progression of atherosclerosis and substantial arterial calcification. For patients over the age of 60, life expectancy in the United States plummets to less than 4.5 years, with survival rates closely linked to the severity of calcification.

Current Treatment Limitations

Currently, approaches to manage the progression of vascular calcification focus on controlling calcium and phosphate levels. This is typically achieved through dietary adjustments and vitamin D management. However, there are no drugs approved specifically for the treatment of vascular calcification, leaving a significant gap in effective therapeutic options.

First-in-Human Clinical Trial Findings

Study Overview

A recent study published in The British Journal of Clinical Pharmacology details a clinical trial conducted by researchers from Spain to assess the safety, tolerability, and pharmacokinetics of a new drug that inhibits calcification. The investigational drug, SNF472, is an intravenous formulation containing the naturally occurring substance IP6, which has shown potential in managing calcium-related disorders.

Trial Design and Methodology

This first-in-human trial was a double-blind, randomized, placebo-controlled study conducted across three hospitals in the United Kingdom. Eight male participants, aged between 45 and 74 years, were randomly assigned to receive either SNF472 or a matching placebo while undergoing standard hemodialysis three times a week. Throughout the study, patients were monitored for hypocalcemia by tracking their vital signs and measuring blood calcium levels after receiving various doses and dosing schedules.

Significance of Results

Safety and Efficacy Outcomes

The findings of this trial indicate a promising safety profile and tolerability for SNF472. Notably, patients who received the drug demonstrated an impressive 80% reduction in calcium crystallization levels. These results underscore the potential benefits of SNF472 as a calcification inhibitor for individuals facing the severe impacts of accelerated vascular calcification.

Future Availability of SNF472

Given the encouraging outcomes, there is optimism regarding the eventual market availability of this experimental drug. As researchers continue to explore its efficacy, SNF472 may soon provide a much-needed treatment option for patients affected by vascular calcification.

Reference

Perelló J. et al. First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification. British Journal of Clinical Pharmacology. 2018. DOI: 10.1111/bcp.13752.